Angiogenically effective unit dose of fgf-2 and method of use
AssigneeNovartis Vaccines and Diagnostics, Inc.
InventorMartha Jo Whitehouse
Life of this patent
Estimating the term…
Abstract
The present invention provides a unit dose composition comprising 0.2 μg/kg to 48 μg/kg of an FGF-2 of SEQ ID NO:2, or an angiogenically active fragment or mutein thereof in a pharmaceutically acceptable carrier. Also provided is a method for treating a human patient for coronary artery disease, comprising administering into one or more coronary vessels or a peripheral vein of said patient a safe and angiogenically effective dose of a recombinant FGF-2, or an angiogenically active fragment or mutein thereof. Also provided is a pharmaceutical composition comprising a therapeutically effective amount of FGF-2, alone or in combination with heparin, in a therapeutically effective carrier.
Claims9
A method for treating a human patient for a myocardial infarction, comprising administering a single unit dose of a recombinant fibroblast growth factor-2 (FGF-2) or an angiogenically active fragment or an angiogenically active mutein thereof into one or more coronary vessels or into a peripheral vein in a human patient in need of treatment for coronary artery disease or a myocardial infarction, said unit dose comprising from about 0.008 mg to 7.2 mg of said recombinant FGF-2 or said angiogenically active fragment or said angiogenically active mutein thereof, wherein said recombinant FGF-2 has the amino acid sequence of human FGF-2, and wherein said angiogenically active mutein has at least 90% amino acid sequence identity with human FGF-2.
A method for inducing angiogenesis in a heart of a human patient, comprising administering a single unit dose of a recombinant fibroblast growth factor-2 (FGF-2) or an angiogenically active fragment or an angiogenically active mutein thereof into one or more coronary vessels or into a peripheral vein in a human patient in need of treatment for coronary artery disease, said unit dose comprising from about 0.008 mg to 7.2 mg of said recombinant fibroblast growth factor-2 (FGF-2) or said angiogenically active fragment or said angiogenically active mutein thereof, wherein said recombinant FGF-2 has the amino acid sequence of human FGF-2, and wherein said angiogenically active mutein has at least 90% amino acid sequence identity with human FGF-2.
A method for providing a human patient with relief from symptoms of angina, comprising administering a single unit dose of a recombinant fibroblast growth factor-2 (FGF-2) or an angiogenically active fragment or an angiogenically active mutein thereof into one or more coronary vessels or into a peripheral vein in a human patient in need of relief from symptoms of angina, said unit dose comprising from about 0.008 mg to 7.2 mg of said recombinant fibroblast growth factor-2 (FGF-2) or said angiogenically active fragment or said angiogenically active mutein thereof, wherein said recombinant FGF-2 has the amino acid sequence of human FGF-2, and wherein said angiogenically active mutein has at least 90% amino acid sequence identity with human FGF-2.
Dependencies are inferred from the claim text.